secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001171843-23-004433
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus appoints Karen Sims as CMO, Christopher Naftzger as GC and CCO
----------------------------------------------------------------------

- Dr. Karen Sims promoted from VP Clinical Development to Chief Medical Officer, effective immediately.
- Christopher Naftzger appointed General Counsel and Chief Compliance Officer; Dr. Elizabeth Howard remains advisor on patent litigation.
- Naftzger granted inducement option for 500,000 common shares at July 10, 2023 closing price, vesting over 4 years.
- Sims has 12+ years experience, previously at Bristol-Myers Squibb; Naftzger has 25+ years legal experience, most recently at Nabriva Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004433/0001171843-23-004433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004433/f8k_070723.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer